Journal of Clinical Oncology
Articles in this Issue
The spectrum of bevacizumab-induced renal injury: A systematic review of published case reports.
e24143 Background: Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is widely used...
From eligibility to enrollment: Evaluating barriers to clinical trial participation for leiomyosarcoma (LMS) at MD Anderson Cancer Center (MDACC).
e23531 Background: LMS is a rare, aggressive malignant tumor of smooth muscle origin, and its clinical heterogeneity compl...
Prognostic value of ultra-low PSA after 3 and 6 months of intensified androgen deprivation therapy in patients with metastatic castration-sensitive prostate cancer: Real-world data from a single healthcare center in Caracas, Venezuela.
e17110 Background: Prostate cancer is the most frequent cause of cancer-related morbidity worldwide in men, with a nationa...
Immune microenvironment, MSI status, and tumor mutational burden as prognostic factors in colorectal cancer.
e14524 Background: Immune checkpoint inhibition has demonstrated meaningful clinical benefit in microsatellite instability...
Impact of time-to-surgery on survival outcomes in Korean breast cancer patients: A nationwide population-based cohort study.
581 Background: The increasing incidence of breast cancer and the resulting surgical workload in South Korea have led to c...
Liquid-based methylation profiling of molecular breast cancer subtypes (MBS) in hormone receptor positive (HR+) metastatic breast cancer (MBC) treated with CDK4/6 inhibitor (CDK4/6i).
1095 Background: MBC remains incurable due to the invariable development of resistance, with most deaths resulting from HR...
Infection burden with BCMA versus GPRC5D-targeted bispecific antibodies in multiple myeloma: A systematic review and meta-analysis.
e19511 Background: The approved B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (...
Urinary tumor DNA–guided de-escalation of systemic immunotherapy in extensive very high risk non–muscle-invasive bladder cancer.
4593 Background: Non-muscle-invasive bladder cancer (NMIBC) has entered the era of systemic immunotherapy. Large randomize...
Phase II study of cemiplimab ± fianlimab following SBRT for oligometastatic clear-cell RCC (LAG-BOOST).
TPS4637 Background: Oligometastatic clear-cell renal cell carcinoma (ccRCC) is a biologically distinct, often indolent sta...
Breast cancer survivor perspectives on nutrition: Results of a comprehensive survey.
e22674 Background: The majority of patients gain weight during breast cancer (BC) treatment. Weight gain is often distress...
Role of trilaciclib against chemotherapy-induced myelosuppression: An updated systematic review and meta-analysis.
e24158 Background: Trilaciclib, a reversible CDK4/6 inhibitor, is used before chemotherapy to reduce myelosuppression. We...
Machine learning model for lung cancer risk stratification using routine complete blood count exams.
e20005 Background: Lung cancer remains the leading cause of cancer-related mortality worldwide, largely due to late-stage...
CXCL9:SPP1 ratio: Macrophage polarization and outcomes with pembrolizumab or enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer.
4573 Background: Enfortumab vedotin plus pembrolizumab (EV+P) is standard first-line treatment for metastatic urothelial c...
Impactof <i>MET</i> amplification (amp) on telisotuzumab vedotin (Teliso-V) efficacy and safety in 2L+ non-squamous (NSQ) <i>EGFR</i> wild-type (WT) NSCLC with c-Met protein overexpression (OE).
8524 Background: Teliso-V is a c-Met–directed antibody-drug conjugate comprising telisotuzumab and the microtubule polymer...
Radiation for oligoprogression to prolong systemic therapy: Experience from early drug development trials.
e15102 Background: For patients with metastatic cancer treated on an early-phase clinical trial, disease progression typic...
Outcomes of PD-(L)1 inhibitor continuation or rechallenge after first-line progression in recurrent or metastatic head and neck squamous cell carcinoma.
6059 Background: PD-(L)1 inhibitors are a standard first-line (1L) backbone for recurrent or metastatic head and neck squa...
Inhalable polyphenolic-based nanoparticles for localized lung cancer treatment.
e20758 Background: Lung cancer remains a leading cause of cancer-related morbidity and mortality worldwide. Although conve...
First-in-human study of DM002, an anti-MUC1/HER3 bispecific antibody-drug conjugate, in patients with advanced solid tumors.
3037 Background: DM002 is a bispecific ADC (BsADC) conjugated to BLD1102, a linker/payload system composed of a linker and...
Clinical efficacy and safety of BM201 intra-tumoral injection and radiotherapy in advanced solid tumors: Results from the phase I/IIT study.
2599 Background: For vaccine design, an antigen and an adjuvant are necessary for an effective immune response. In the con...
Incidence of cardiac-related deaths (CRDs) among patients (pts) aged ≥ 65 years with B-cell malignancies (BCMs) treated with ibrutinib (ibr).
e19020 Background: Ibr is associated with increased risk of fatal cardiac failure in clinical trials; however, real-world...
Longitudinal on-treatment plasma microRNA profiling for identification of biomarker signatures associated with gemcitabine/nab-paclitaxel therapy in pancreatic ductal adenocarcinoma.
e16387 Background: Pancreatic ductal adenocarcinoma (PDAC) is associated with poor outcomes and limited benefit from syste...
Efficacy and safety of darolutamide plus androgen deprivation therapy in de novo metastatic hormone-sensitive prostate cancer: A single-center retrospective study.
e17085 Background: ADT alone provides limited benefit in mHSPC, with most patients progressing to castration resistance. D...
Impact of symptom burden, psychological distress, and treatment accessibility on quality of life in people with cancer in Syria.
11046 Background: In low-resource and conflict-affected settings, barriers to cancer care may amplify symptom burden and p...
Trends in thyroid cancer mortality among adults in the United States and Puerto Rico, 1999–2021.
e18023 Background: Thyroid cancer is a leading endocrine malignancy characterized by rising global incidence. Despite adva...
Lycopene and survival in patients with stage III colon cancer: Findings from CALGB (Alliance)/SWOG 80702.
3630 Background: Lycopene, a non-provitamin A carotenoid, has been reported to inhibit colon cancer development; however,...